Sisram Medical Ltd (HKG:1696)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 1.27B -34.2% |
| Revenue (ttm) | 2.84B +4.7% |
| Net Income | 148.01M -24.3% |
| EPS | 0.32 -24.3% |
| Shares Out | 468.34M |
| PE Ratio | 8.58 |
| Forward PE | 5.58 |
| Dividend | 0.10 (3.51%) |
| Ex-Dividend Date | Aug 26, 2025 |
| Volume | 460,640 |
| Open | 2.750 |
| Previous Close | 2.740 |
| Day's Range | 2.680 - 2.790 |
| 52-Week Range | 2.650 - 8.070 |
| Beta | 0.80 |
| Analysts | Strong Buy |
| Price Target | 4.40 (+62.36%) |
| Earnings Date | Mar 23, 2026 |
About Sisram Medical
Sisram Medical Ltd, together with its subsidiaries, engages in the research, design, development, manufacture, sale, and marketing of medical aesthetics and dental equipment, home-use devices, injectables, and cosmeceutical products in the Asia Pacific, North America, Europe, the Middle East, Africa, and Latin America. The company offers a portfolio of products and treatments for clinical aesthetic indications, including hair removal, skin rejuvenation, acne and acne scars, trans-epidermal delivery, face and body contouring, cellulite treatment... [Read more]
Financial Performance
In 2025, Sisram Medical's revenue was $365.35 million, an increase of 4.65% compared to the previous year's $349.11 million. Earnings were $19.02 million, a decrease of -24.32%.
Financial numbers in USD Financial StatementsNews
Sisram Medical Investor Day Key Takeaways
Advancing Global Medical Aesthetics Strategy and Unl ock ing Wellness Platform Value HONG KONG, May 27, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK), a global wellness ...
Geographic diversification is key to resilience, says Israel-based Sisram Medical
Lior Dayan of Hong Kong-listed Israeli firm Sisram Medical discusses the company’s 2025 earnings. He adds that Sisram’s expansion into direct operations across Asia Pacific has strengthened its resili...
Sisram Medical Earnings Call Transcript: H2 2025
Revenue grew 4.7% to $365M in 2025, led by APAC and injectables, while North America declined. Gross margin fell to 58.9% due to tariffs and mix, but adjusted net profit rose 7.9%. DAXXIFY launched in China, and AI-enabled solutions expanded globally.
Sisram Medical Earnings release: H2 2025
Sisram Medical released its H2 2025 earnings on March 24, 2026, summarizing the period's financial results.
Sisram Medical Slides: H2 2025
Sisram Medical has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 24, 2026.
Sisram Medical Annual report: H2 2025
Sisram Medical has published its H2 2025 annual report on March 24, 2026.
Sisram Medical Reports Solid Growth in 2025
Solid growth driven by strong performance in international markets, with the injectables business accelerating rapidly DAXXIFY shows promising results from initial commercialization in China, with exp...
Sisram Medical to Announce 2025 Annual Results on Monday, March 23, 2026
Earnings Conference Call to be Held on March 24, 2026 HONG KONG, March 12, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively refe...
Alma, a Sisram Medical Company, Advances the Future of Intelligent Aesthetics at IMCAS World Congress 2026
New clinical evidence highlights a smarter, technology-driven approach to scar management, rejuvenation, and tattoo removal HONG KONG, Feb. 5, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or...
Sisram Medical Partners with Sinmait Medical Technology to Build Next-Generation Manufacturing and Innovation Hub in China
HONG KONG, Jan. 21, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively referred to as the "Group"), a global wellness group offeri...
Sisram Medical Reports Completion of NIFDC Testing for DAXXIFY in China
Marking a Key Milestone Toward Market Launch and Strengthening Sisram's Premium Aesthetics Portfolio HONG KONG, Jan. 5, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; tog...
Sisram Medical Launches Universkin by Alma in Hong Kong, Pioneering a New Era of AI-assisted Personalized Skincare
HONG KONG , Nov. 21, 2025 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively referred to as the "Group"), a global consumer wellness gr...
Sisram Medical Delivers Strong Third-Quarter 2025 Performance with Robust Momentum Across Key Markets and Core Businesses
HONG KONG , Oct. 28, 2025 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively referred to as the "Group"), a global consumer wellness gr...
Sisram Medical Earnings Call Transcript: H1 2025
Revenue for H1 2025 declined 1.9% to $165.5 million, with strong growth in Asia-Pacific offsetting North American weakness. Injectables revenue surged 218%, and new launches like Daxxify and Universe Skin are expected to drive H2 growth.
Sisram Medical Quarterly report: H1 2025
Sisram Medical has published its H1 2025 quarterly earnings report on August 21, 2025.
Sisram Medical Earnings release: H1 2025
Sisram Medical released its H1 2025 earnings on August 21, 2025, summarizing the period's financial results.
Sisram Medical Slides: H1 2025
Sisram Medical has posted slides in relation to its H1 2025 quarterly earnings report, which was published on August 21, 2025.
Sisram Medical Earnings Call Transcript: H2 2024
Revenue declined 2.8% to $349.1M in 2024, but gross margin improved to 62.1% and direct sales rose to 87% of revenue. New launches and injectables commercialization in China are expected to drive growth in 2025, despite ongoing macroeconomic and regional risks.
Sisram Medical Annual report: H2 2024
Sisram Medical has published its H2 2024 annual report on March 20, 2025.
Sisram Medical Earnings release: H2 2024
Sisram Medical released its H2 2024 earnings on March 20, 2025, summarizing the period's financial results.
Sisram Medical Slides: H2 2024
Sisram Medical has posted slides in relation to its H2 2024 quarterly earnings report, which was published on March 20, 2025.
Sirsram Medical announces NMPA approval for DAXXIFY®
Marking the introduction of the world's first and only peptide-powered botulinum toxin product to Mainland China HONG KONG , Sept. 9, 2024 /PRNewswire/ -- Sisram Medical (1696.HK), a global leading in...